Rilzabrutinib: rationale and selectivity

Hanny Al-Samkari outlines rilzabrutinib's targeted BTK inhibition, reduced platelet aggregation effects, and autoimmune focus.

Play episode from 11:53

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!